Contact Marin & Murphy
Marin & Murphy is licensed in South Carolina, Massachusetts, Rhode Island, and Connecticut, and works with lawyers licensed across the country.
Marin & Murphy is not licensed in the District of Columbia; a matter there would be handled with, or referred to, a lawyer licensed in that state.
Dupixent — CTCL Litigation
The Dupixent Litigation, Explained
Federal cases are consolidated in MDL 3180, most cases are in their earliest stages, and no settlement exists. Here is what is publicly known.
ACTIVE LITIGATION — NO SETTLEMENT. MDL 3180 underway · deadlines vary by state.
Marin & Murphy is not licensed in the District of Columbia; details below.
Partners
Stefanie A. Murphy & Matthew T. Marin
Super Lawyers® honorees · members of the American Association for Justice · concentrating in personal injury and mass-tort litigation.
No settlement has been reached in the Dupixent litigation, and most cases are in their earliest stages. Every case must be proven on its own facts. Whether any patient has a claim depends on the facts and the law of their state. The information below covers the litigation itself.
Marin & Murphy Law Firm is not licensed in the District of Columbia; details below.
For readers in the District of Columbia the essentials are the same: plaintiffs allege an association between Dupixent (dupilumab) and cutaneous T-cell lymphoma, no court has found Dupixent causes CTCL, and no settlement exists. Whether any individual has a claim depends on their medical records and the law of their state. The information below covers the litigation itself.
Where the Dupixent CTCL Litigation Stands
Made by Sanofi and Regeneron and prescribed in the District of Columbia as it is across the country, Dupixent (dupilumab) is a prescription biologic, FDA-approved since March 2017, now carrying nine indications, including atopic dermatitis, asthma, and COPD. In June 2026 — the date that also governs cases from the District of Columbia — the Judicial Panel on Multidistrict Litigation centralized the pending federal cases as MDL 3180 in the United States District Court for the District of New Jersey, before Judge Zahid N. Quraishi. The complaints in the consolidated Dupixent lawsuit allege that the drug is associated with an increased risk of cutaneous T-cell lymphoma (CTCL) and that the manufacturers failed to warn patients and doctors. As of November 2, 2026, 40 cases were pending in the MDL that would govern any filing from the District of Columbia; the current count and its method are kept on the MDL 3180 tracker. No merits ruling exists anywhere, the District of Columbia included, and neither does any settlement.
What the Filings Claim — and What Remains Unproven
For readers in the District of Columbia: what is alleged is an association, and nothing has been adjudicated. Published studies report a statistical association between dupilumab and CTCL — an association the study authors themselves note does not establish causation — and the FDA has identified a potential safety signal for CTCL that it is still evaluating. No lymphoma or malignancy warning appears on Dupixent’s current label, in the District of Columbia or anywhere else. The FDA adverse event reports connected to this question are agency reports, not verified causes, and the courts have decided nothing on the merits — in the District of Columbia or anywhere else.
Is Anyone From the District of Columbia Already in the Dupixent Litigation?
Possibly, but the public record does not yet let us say so responsibly. All federal Dupixent CTCL cases are consolidated in MDL 3180 in the District of New Jersey, and the MDL’s member-case complaints are mostly not in the free public record; a case’s original filing court also does not establish where the plaintiff lives. This page therefore reports the litigation’s overall posture through the MDL 3180 tracker rather than an unverified District of Columbia figure, and it will describe a District of Columbia resident’s case when a publicly available complaint documents one.
Who Is Covered by the Filed Cases?
The consolidated cases — whether from the District of Columbia or elsewhere — involve people who used Dupixent and were diagnosed with cutaneous T-cell lymphoma or a related T-cell lymphoma subtype during or after that use. The claims carry no minimum-use requirement, and in the District of Columbia, estates of patients who have died may bring claims under state wrongful-death and survival statutes. Whether any individual’s circumstances resemble the filed cases is a question of medical records and state law, not of headlines — and for a District of Columbia resident, it is a question for an attorney licensed in the District of Columbia.
The District of Columbia’s Federal Courts and the Path to MDL 3180
The District of Columbia has one federal district court: the United States District Court for the District of Columbia. A Dupixent CTCL suit filed there does not stand alone: through the Judicial Panel on Multidistrict Litigation, these cases are centralized as MDL 3180 before Judge Zahid N. Quraishi in the United States District Court for the District of New Jersey, so a District of Columbia case is transferred to the MDL for coordinated pretrial proceedings — or, where the MDL court’s case-management orders permit, filed in the District of New Jersey directly. Either route leads to the same consolidated proceeding, and a case from the District of Columbia remains an individual claim; an MDL is not a class action.
Filing Deadlines Under District of Columbia Law
The District of Columbia’s general statute of limitations for personal-injury claims is three years under D.C. Code § 12-301(8). The District of Columbia applies a discovery rule requiring knowledge of the injury, of its cause in fact, and of some evidence of wrongdoing before the claim accrues. How a limitations period applies to any specific CTCL diagnosis depends on the dates in the medical records, the legal theory pleaded, and District of Columbia tolling and accrual doctrine. An attorney licensed in the District of Columbia can evaluate whether a claim is timely.
How Common Is CTCL in the District of Columbia?
The District of Columbia is home to about 700,000 people (U.S. Census Bureau, 2024 estimate). Cutaneous T-cell lymphoma is rare — roughly 8.55 new cases per million person-years (SEER) — which works out to on the order of 6 new CTCL diagnoses across the District of Columbia in a typical year. Rarity means the numbers on this page cannot answer an individual question — in the District of Columbia, any one claim is decided by medical records read against state law.
About Marin & Murphy Law Firm and District of Columbia
Marin & Murphy Law Firm is a personal-injury and mass-tort law firm; its attorneys’ individual admissions are listed at the bottom of this page, and this page is published as litigation information. Marin & Murphy Law Firm is not licensed in the District of Columbia. The firm does not accept District of Columbia legal matters; inquiries from District of Columbia residents are referred to attorneys licensed in District of Columbia. Some matters may be referred to other lawyers. An attorney licensed in the District of Columbia can evaluate whether a claim is timely and how District of Columbia law applies to a particular diagnosis.
District of Columbia Dupixent Litigation FAQs
Are there Dupixent lawsuits in District of Columbia courts?
Rather than proceeding separately around the country, the federal cases — filings from the District of Columbia included — are consolidated in MDL 3180 in the District of New Jersey. A Dupixent CTCL case filed in a District of Columbia federal court is subject to transfer into that consolidated proceeding. This page does not track filings outside the federal system.
Who is included in the filed cases?
People — from the District of Columbia or anywhere — who used Dupixent and were diagnosed with cutaneous T-cell lymphoma or a related T-cell lymphoma subtype during or after that use. There is no minimum-use requirement, and estates of patients who have died — in the District of Columbia as elsewhere — bring claims under state wrongful-death and survival statutes.
Has any court found that Dupixent causes CTCL?
No. Plaintiffs allege an association; published studies report a statistical association that their authors note does not establish causation; the FDA is still evaluating a potential safety signal; and the Dupixent label — the same one dispensed in the District of Columbia — currently contains no lymphoma warning.
Is there a Dupixent settlement?
No. No settlement exists and no court has ruled on the merits — the litigation, claims from the District of Columbia included, is in its earliest stages. A number implying otherwise, wherever a reader in the District of Columbia saw it, did not come from the docket.
What is the filing deadline for a District of Columbia Dupixent claim?
Filing deadlines come from District of Columbia statutes and court doctrine, and more than one rule can bear on when the period begins to run; the section above covers what is settled and what is not. An attorney licensed in the District of Columbia can evaluate whether a claim is timely.
Does Marin & Murphy Law Firm accept District of Columbia cases?
No. Marin & Murphy Law Firm is not licensed in the District of Columbia and does not accept District of Columbia legal matters; inquiries from District of Columbia residents are referred to attorneys licensed in the District of Columbia.
Nearby states
How Common Is Dupixent in the District of Columbia? The Public Numbers
In the District of Columbia, Dupixent (dupilumab) is a common prescription for atopic dermatitis and related inflammatory conditions. State-level federal utilization data captures the scale of its use:
Between 2024 and 2025, Medicaid prescriptions reported in the District of Columbia increased around 7%. These counts reflect Medicaid outpatient reporting alone; prescriptions covered by Medicare or private insurance are not included, so the true number of residents of the District of Columbia using Dupixent is larger. A small number of privacy-suppressed records are excluded from the totals.
Sources: Centers for Medicare & Medicaid Services, State Drug Utilization Data 2024 and 2025 (accessed August 21, 2026); In re: Dupixent (Dupilumab) Products Liability Litigation, MDL No. 3180, JPML Transfer Order, Schedule A (June 4, 2026). Utilization data reflects prescriptions reported by state Medicaid programs and is not evidence that any individual prescription caused injury.
Sources
- U.S. Judicial Panel on Multidistrict Litigation, Pending MDL Dockets by MDL Number (November 2, 2026) — jpml.uscourts.gov
- MDL 3180 docket records — CourtListener dockets 72288297 (JPML) and 73443394 (D.N.J. 3:26-md-03180), reviewed September 15, 2026.
- D.C. Code § 12-301(8) — District of Columbia statute of limitations discussed above.
- U.S. Census Bureau, Vintage 2024 Population Estimates (NST-EST2024), resident population as of July 1, 2024.
- SEER program data: cutaneous T-cell lymphoma incidence ≈8.55 cases per million person-years.
Marin & Murphy Law Firm is not licensed in the District of Columbia. The firm does not accept District of Columbia legal matters; inquiries from District of Columbia residents are referred to attorneys licensed in District of Columbia. Some matters may be referred to other lawyers.
Attorney admissions: Matthew T. Marin — RI, CT, MA, SC, U.S.D.C. D.R.I. · Stefanie A. Murphy — RI, CT, MA, U.S.D.C. D.R.I./D.Conn./D.Mass.
Attorney Advertising.
Attorney Advertising. This page is for general information and is not legal advice; reading it does not create an attorney-client relationship, and no attorney-client relationship is formed until a written engagement agreement is signed. Marin & Murphy Law Firm is a national mass tort and personal injury law firm with offices in Rhode Island and South Carolina, representing injured people and families nationwide. The firm’s mass-tort practice is directed from its Charleston, South Carolina office. Where a matter arises in a state in which our attorneys are not admitted, we work with lawyers licensed in that state. Responsible attorney: Matthew T. Marin, 997 Morrison Drive, Suite 200, Charleston, SC 29403. Whether a claim is accepted is determined after review. No representation is made that the quality of legal services is greater than that of other lawyers. Prior results do not guarantee a similar outcome; every case depends on its own facts.
Where we practice
Marin & Murphy Law Firm is a national mass tort and personal injury law firm with offices in Rhode Island and South Carolina, representing injured people and families nationwide. Where a matter arises in a state in which our attorneys are not admitted, we work with lawyers licensed in that state. We are not licensed in the District of Columbia. The firm does not accept the District of Columbia legal matters; inquiries from the District of Columbia residents are referred to attorneys licensed in the District of Columbia. This page is attorney advertising and is provided for general information; it is not legal advice, and reading it does not create an attorney–client relationship.